查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
僵直性脊椎炎市场 - 成长、未来前景、竞争分析，2023-2031
市场调查报告书
商品编码
1422211

僵直性脊椎炎市场 - 成长、未来前景、竞争分析，2023-2031

Ankylosing Spondylitis Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 114 Pages | 商品交期: 最快1-2个工作天内

价格

僵直性脊椎炎 (AS) 是一种慢性发炎性疾病，主要影响脊柱，导致疼痛、僵硬和运动障碍。在生物疗法的进步、透过支持计画以患者为中心的方法以及导致早期诊断的意识提高的推动下，强直性脊椎炎市场预计在2024 年至2032 年预测期内将以8.5% 的复合年增长率增长。然而，生物疗法的高成本是一个重大的阻碍。市场区隔反映了对 AS 药物的动态偏好和疾病盛行率的区域差异。从地区来看，北美对营收贡献显着，而亚太地区则显示出强劲的成长潜力。竞争趋势凸显了Novartis、AbbVie和Janssen等大公司所采取的策略。这些公司利用技术创新、患者支援和全球市场扩张来保持竞争力。随着僵直性脊椎炎市场从 2023 年发展到 2032 年的预测期，需要解决成本障碍，以确保持续成功地改善受这种慢性发炎性疾病影响的人们的生活。保持以患者为中心的方法和适应当地的细微差别。

生物製剂的进展

TNF抑制剂等生物製剂的进步极大地促进了这种疾病的治疗。Cosentyx、Humira 和 Enbrel 等药物已显示出在减少发炎、控制症状和改善 AS 患者整体生活品质方面的功效。临床试验和现实世界研究的证据显示了这些生物疗法的正面影响。例如，Cosentyx 的有效性已被证明可以持续改善 AS 症状和功能。这些生物製剂仍然处于 AS 治疗的最前沿，它们的持续开发和采用正在促进市场成长。

以病人为中心的方法和支持计划

以患者为中心的方法，加上製药公司提供的全面支持计划，正在推动僵直性脊椎炎市场的发展。提供 AS 药物的公司，如 Simponi、Remicade 和 Cimzia，已经启动了支持计划，帮助患者获得药物、管理副作用并遵守治疗计划。证据包括患者的感言和现实生活经历，强调了这些支持计划对治疗依从性和患者结果的正面影响。随着公司继续优先考虑患者福祉和整体护理，以患者为中心的方法预计将在维持市场成长方面发挥关键作用。

提高认识和早期诊断

对僵直性脊椎炎的认识不断提高以及早期诊断的努力正在对市场产生积极影响。医疗保健组织、患者权益团体和製药公司的努力正在帮助提高人们对该疾病症状和早期介入重要性的认识。这一点可以从诊断病例的增加和旨在早期发现 AS 的筛检计划的实施中看出。早期诊断可以及时介入并开始有效的治疗，从而实现更好的疾病管理。随着意识活动继续对医疗保健专业人员和公众进行教育，早期诊断的趋势预计将持续存在并推动 AS 市场的成长。

生物製剂成本高

用生物製剂治疗僵直性脊椎炎的高成本是进入市场的主要障碍。儘管 Cosentyx 和 Humira 等药物有效，但它们给患者和医疗保健系统带来了巨大的经济负担。证据包括强调生物治疗的成本效益挑战的经济评估和研究。经济负担可能会限制某些患者的治疗并阻碍最佳的疾病管理。儘管存在患者援助计划，但解决生物製剂高成本这一首要问题对于确保公平获得有效的僵直性脊椎炎治疗至关重要。

药物细分 Cosentyx、Humira 和 Enbrel 主导市场

2023年，僵直性脊椎炎市场销售量最高的是Cosentyx、Humira、Enbrel等药物。然而，Chimjia 在预测期内（2024-2032 年）的复合年增长率（CAGR）最高。这种动态成长是由患者和医疗保健提供者的独特属性和不断变化的偏好所驱动的。Cimzia 在控制 AS 症状和改善患者治疗效果方面的有效性得到了研究和现实世界证据的支持。随着僵直性脊椎炎治疗模式的发展，受安全性和患者反应等因素的影响，药物偏好可能会改变。

北美仍处于世界领先地位

按地区划分，北美在 2023 年的销售额中所占份额最高，反映出其医疗基础设施完善且普及率高。然而，预计亚太地区在预测期内的复合年增长率最高。这是基于亚太国家对 AS 认识的提高、获得医疗保健的机会的改善以及治疗方案的不断发展。这些地理趋势突显出需要製定量身定制的策略来解决疾病流行、治疗偏好和医疗保健基础设施方面的区域差异。

预测期内市场竞争将加剧

2023年，僵直性脊椎炎市场的主要参与者包括Novartis, AbbVie, Janssen, Amgen, UCB, Pfizer, Eli Lilly & Company, Johnson & Johnson Services, Merck & Company等。这些公司采用不同的策略，包括研发、病患支援活动和市场拓展工作。新的治疗方案、患者援助计划以及与医疗保健专业人员和患者倡导团体的合作关係的持续发展证明了这一点。截至 2023 年，竞争格局显示市场充满活力，各公司都在努力增强其产品供应和支援结构。2023 年收入和预测期（2024-2032 年）揭示了竞争格局，其中技术创新、以患者为中心的方法和全球策略是成功的关键。

目录

第一章 前言

  • 报告内容
    • 报告目的
    • 目标听众
    • 主要提供产品
  • 市场细分
  • 调查方法
    • 第一阶段—二次调查
    • 第二阶段-初步调查
    • 第三阶段-专家评审
    • 先决条件
    • 采取的方法

第二章执行摘要

第三章僵直性脊椎炎市场：竞争分析

  • 主要供应商的市场地位
  • 供应商采取的策略
  • 主要产业战略
  • 等级分析：2023 年 vs 2032 年

第四章僵直性脊椎炎市场：宏观分析与市场动态

  • 介绍
  • 2022-2032年全球僵直性脊椎炎市场价值
  • 市场动态
    • 市场驱动力
    • 市场制约因素
    • 主要问题
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析
  • 波特的五力模型
    • 供应商实力
    • 购买力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争对手之间的竞争
  • PESTEL 分析
    • 政局
    • 金融情况
    • 技术景观
    • 法律状况
    • 社会局势

第五章僵直性脊椎炎市场：依药物分类 2022-2032

  • 市场概况
  • 成长/利润分析：2023 年与 2032 年
  • 2022-2032年数量和价格分析
  • 市场细分
    • cosentics
    • humira
    • Simponi
    • remicade
    • Enbrel
    • Cimzia
    • 其他

第 6 章 僵直性脊椎炎市场：依通路划分 2022-2032 年

  • 市场概况
  • 成长/利润分析：2023 年与 2032 年
  • 2022-2032年数量和价格分析
  • 市场细分
    • 医院药房
    • 零售药店
    • 网上药店

第7章北美僵直性脊椎炎市场2022-2032

  • 市场概况
  • 僵直性脊椎炎市场：依药物分类 2022-2032
  • 僵直性脊椎炎市场：依分销管道划分 2022-2032
  • 僵直性脊椎炎市场：依地区划分 2022-2032
    • 北美
      • 美国
      • 加拿大
      • 其他北美

第 8 章英国与欧盟僵直性脊椎炎市场 2022-2032

  • 市场概况
  • 僵直性脊椎炎市场：依药物分类 2022-2032
  • 僵直性脊椎炎市场：依分销管道划分 2022-2032
  • 僵直性脊椎炎市场：依地区划分 2022-2032
    • 英国和欧盟
      • 英国
      • 德国
      • 西班牙
      • 义大利
      • 法国
      • 欧洲其他地区

第9章亚太地区僵直性脊椎炎市场2022-2032

  • 市场概况
  • 僵直性脊椎炎市场：依药物分类 2022-2032
  • 僵直性脊椎炎市场：依分销管道划分 2022-2032
  • 僵直性脊椎炎市场：依地区划分 2022-2032
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 亚太其他地区

第10章拉丁美洲僵直性脊椎炎市场2022-2032

  • 市场概况
  • 僵直性脊椎炎市场：依药物分类 2022-2032
  • 僵直性脊椎炎市场：依分销管道划分 2022-2032
  • 僵直性脊椎炎市场：依地区划分 2022-2032
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地区

第十一章中东和非洲僵直性脊椎炎市场2022-2032

  • 市场概况
  • 僵直性脊椎炎市场：依药物分类 2022-2032
  • 僵直性脊椎炎市场：依分销管道划分 2022-2032
  • 僵直性脊椎炎市场：依地区划分 2022-2032
    • 中东/非洲
      • GCC
      • 非洲
      • 其他中东/非洲地区

第十二章公司简介

  • Novartis
  • AbbVie
  • Janssen
  • Amgen
  • UCB
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • 其他主要公司
Product Code: 140059-01-24

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine, causing pain, stiffness, and impaired mobility. The ankylosing spondylitis market is expected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2032, propelled by advancements in biological therapies, a patient-centric approach with support programs, and increasing awareness leading to early diagnosis. However, the high cost of biologic therapies poses a notable restraint. Market segmentation reflects the dynamic preferences for AS drugs and regional variations in disease prevalence. Geographically, North America contributes significantly to revenue, while the Asia-Pacific region presents high growth potential. Competitive trends highlight the strategies adopted by major players, including Novartis, AbbVie, and Janssen. These companies leverage innovation, patient support, and global market expansion to maintain a competitive edge. As the ankylosing spondylitis market progresses from 2023 to the forecast period of 2032, addressing cost barriers, sustaining patient-centric approaches, and adapting to regional nuances will be critical for continued success in improving the lives of individuals affected by this chronic inflammatory condition.

Advancements in Biologic Therapies

Advances in biologic therapies, such as TNF inhibitors, have significantly contributed to the treatment landscape of ankylosing spondylitis. Medications like Cosentyx, Humira, and Enbrel have shown efficacy in reducing inflammation, managing symptoms, and improving the overall quality of life for AS patients. The evidence lies in clinical trials and real-world studies that showcase the positive impact of these biological therapies. For instance, studies demonstrate the effectiveness of Cosentyx in achieving sustained improvement in AS symptoms and functionality. As these biologics continue to be at the forefront of AS treatment, their ongoing development and adoption contribute to the market's growth.

Patient-Centric Approach and Support Programs

A patient-centric approach, coupled with comprehensive support programs provided by pharmaceutical companies, has become a driving force in the ankylosing spondylitis market. Companies offering AS treatments, such as Simponi, Remicade, and Cimzia, have initiated support programs to assist patients in accessing medications, managing side effects, and adhering to treatment plans. The evidence lies in patient testimonials and real-world experiences that highlight the positive impact of these support programs on treatment adherence and patient outcomes. As companies continue to prioritize patient well-being and holistic care, the patient-centric approach is anticipated to play a pivotal role in sustaining the market's growth.

Increasing Awareness and Early Diagnosis

The growing awareness of ankylosing spondylitis and efforts to achieve early diagnosis have positively influenced the market. Initiatives by healthcare organizations, patient advocacy groups, and pharmaceutical companies have contributed to increased awareness about the disease's symptoms and the importance of early intervention. The evidence lies in the rise in diagnosed cases and the implementation of screening programs that aim to identify AS at an early stage. Early diagnosis allows for timely intervention and the initiation of effective treatments, leading to better disease management. As awareness campaigns continue to educate both healthcare professionals and the general public, the trend toward early diagnosis is expected to persist, fostering the growth of the AS market.

High Cost of Biologic Therapies

The high cost associated with biologic therapies for ankylosing spondylitis poses a significant restraint on market accessibility. Despite their effectiveness, medications like Cosentyx and Humira come with a substantial financial burden for both patients and healthcare systems. The evidence lies in economic evaluations and studies that highlight the cost-effectiveness challenges of biological treatments. The financial strain may lead to limited access for some patients, potentially hindering optimal disease management. While patient assistance programs exist, addressing the overarching issue of the high cost of biologics is crucial for ensuring equitable access to effective AS treatments.

Drug Segmentation: Cosentyx, Humira, and Enbrel Dominate the Market

In 2023, the ankylosing spondylitis market saw the highest revenue from drugs such as Cosentyx, Humira, and Enbrel. However, the highest Compound Annual Growth Rate (CAGR) during the forecast period (2024-2032) is anticipated from Cimzia. This dynamic growth is driven by the specific attributes and evolving preferences of patients and healthcare providers. Studies and real-world evidence support the efficacy of Cimzia in managing AS symptoms and improving patient outcomes. As the landscape of AS treatment evolves, drug preferences may shift, influenced by factors such as safety profiles and patient response.

North America Remains the Global Leader

Geographically, North America contributed the highest revenue percentage in 2023, reflecting the well-established healthcare infrastructure and high prevalence of ankylosing spondylitis cases. However, the Asia-Pacific region is poised to exhibit the highest CAGR during the forecast period. The evidence lies in the increasing awareness of AS, improving healthcare access, and the evolving landscape of treatment options in Asia-Pacific countries. These geographic trends emphasize the need for tailored strategies to address regional variations in disease prevalence, treatment preferences, and healthcare infrastructure.

Market Competition to Intensify during the Forecast Period

In 2023, major players in the ankylosing spondylitis market included Novartis, AbbVie, Janssen, Amgen, UCB, Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., and others. These companies adopted diverse strategies, including research and development, patient support initiatives, and market expansion efforts. The evidence lies in the continuous development of new treatment options, patient assistance programs, and collaborations with healthcare professionals and patient advocacy groups. As of 2023, the competitive landscape indicates a dynamic market where companies strive to enhance their offerings and support systems. Revenues for 2023 and the expected landscape for the forecast period (2024-2032) reveal a competitive environment where innovation, patient-centered approaches, and global strategies are key determinants of success.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofAnkylosing Spondylitis market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Ankylosing Spondylitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

    • Cosentyx
    • Humira
    • Simponi
    • Remicade
    • Enbrel
    • Cimzia
    • Others

Distribution Channel

    • Hospital pharmacy
    • Retail pharmacy
    • Online pharmacy

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Ankylosing Spondylitis market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Ankylosing Spondylitis market?
  • Which is the largest regional market for Ankylosing Spondylitis market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Ankylosing Spondylitis market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Ankylosing Spondylitis market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Ankylosing Spondylitis Market
  • 2.2. Global Ankylosing Spondylitis Market, By Drug, 2023 (US$ Million)
  • 2.3. Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 (US$ Million)
  • 2.4. Global Ankylosing Spondylitis Market, By Geography, 2023 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2023

3. Ankylosing Spondylitis Market: Competitive Analysis

  • 3.1. Market Positioning of Key Ankylosing Spondylitis Market Vendors
  • 3.2. Strategies Adopted by Ankylosing Spondylitis Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2032

4. Ankylosing Spondylitis Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Ankylosing Spondylitis Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Volume and Pricing Analysis, 2022-2032
  • 5.4. Market Segmentation
    • 5.4.1. Cosentyx
    • 5.4.2. Humira
    • 5.4.3. Simponi
    • 5.4.4. Remicade
    • 5.4.5. Enbrel
    • 5.4.6. Cimzia
    • 5.4.7. Others

6. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Volume and Pricing Analysis, 2022-2032
  • 6.4. Market Segmentation
    • 6.4.1. Hospital pharmacy
    • 6.4.2. Retail pharmacy
    • 6.4.3. Online pharmacy

7. North America Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 7.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 7.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

8. UK and European Union Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 8.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 8.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

9. Asia Pacific Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 9.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 9.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

10. Latin America Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 10.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 10.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

11. Middle East and Africa Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 11.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 11.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

12. Company Profile

  • 12.1. Novartis
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. AbbVie
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Janssen
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Amgen
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. UCB
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Pfizer, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Eli Lilly and Company
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Johnson & Johnson Services, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Merck & Co., Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Other Notable Players
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 2 Global Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 3 North America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 4 North America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 5 U.S. Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 6 U.S. Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 7 Canada Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 8 Canada Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 9 Rest of North America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 10 Rest of North America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 11 UK and European Union Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 12 UK and European Union Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 13 UK Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 14 UK Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 15 Germany Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 16 Germany Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 17 Spain Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 18 Spain Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 19 Italy Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 20 Italy Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 21 France Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 22 France Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 23 Rest of Europe Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 24 Rest of Europe Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 25 Asia Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 26 Asia Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 27 China Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 28 China Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 29 Japan Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 30 Japan Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 31 India Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 32 India Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 33 Australia Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 34 Australia Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 35 South Korea Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 36 South Korea Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 37 Latin America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 38 Latin America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 39 Brazil Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 40 Brazil Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 41 Mexico Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 42 Mexico Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 43 Rest of Latin America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 44 Rest of Latin America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 45 Middle East and Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 46 Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 47 GCC Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 48 GCC Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 49 Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 50 Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Ankylosing Spondylitis Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Ankylosing Spondylitis Market: Quality Assurance
  • FIG. 5 Global Ankylosing Spondylitis Market, By Drug, 2023
  • FIG. 6 Global Ankylosing Spondylitis Market, By Distribution Channel, 2023
  • FIG. 7 Global Ankylosing Spondylitis Market, By Geography, 2023
  • FIG. 8 Market Geographical Opportunity Matrix - Global Ankylosing Spondylitis Market, 2023

FIG. 9Market Positioning of Key Ankylosing Spondylitis Market Players, 2023

FIG. 10Global Ankylosing Spondylitis Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

  • FIG. 11 Global Ankylosing Spondylitis Market, By Drug, 2023 Vs 2032, %
  • FIG. 12 Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 Vs 2032, %
  • FIG. 13 U.S. Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 14 Canada Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 15 Rest of North America Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 16 UK Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 17 Germany Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 18 Spain Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 19 Italy Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 20 France Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 21 Rest of Europe Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 22 China Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 23 Japan Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 24 India Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 25 Australia Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 26 South Korea Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 27 Rest of Asia Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 28 Brazil Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 29 Mexico Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 30 Rest of Latin America Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 31 GCC Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 32 Africa Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 33 Rest of Middle East and Africa Ankylosing Spondylitis Market (US$ Million), 2022 - 2032